Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -468K | 0 | 0 | 846K | 0 |
| Operating Income | -315M | -167M | -102M | -91M | -34M |
| EBITDA | -292M | -144M | -92M | -89M | -32M |
| Net Income | -300M | -152M | -96M | -89M | -33M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$35.09
+0.23% today
1Y Change
+61.71%
Window
Jun 23, 2025 → Jun 17, 2026
Coverage: 248 bars · Jun 23, 2025 → Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Vera Therapeutics, Inc. (VERA) is a Healthcare stock with a market cap of $2.52B and listed on NASDAQ. The stock last traded around $35.09 and up 61.7% across the available one-year price window (Jun 23, 2025 → Jun 17, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of -69.5%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS -69.5%, free cash flow -78.2% with operating margin 0.0% and ROIC -46.3%. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines VERA price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
VERA
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
VERA Max Drawdown
-43.85%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for VERA and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$32.6M
+63.4% YoY
Free Cash Flow
-$23.7M
+65.0% YoY
Revenue Growth
+0.0%
EPS Growth
-69.5%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -468K | 0 | 0 | 846K | 0 |
| Operating Income | -315M | -167M | -102M | -91M | -34M |
| EBITDA | -292M | -144M | -92M | -89M | -32M |
| Net Income | -300M | -152M | -96M | -89M | -33M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 355M | 93M | 46M | 43M | 80M |
| Total Assets | 735M | 656M | 176M | 131M | 84M |
| Total Liabilities | 130M | 79M | 74M | 55M | 14M |
| Shareholder Equity | 605M | 577M | 102M | 77M | 70M |
| Total Debt | 77M | 55M | 54M | 31M | 5M |
| Net Debt | -277M | -38M | 8M | -12M | -75M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
24M
+64.9% YoY
Capital Expenditures
0
+100.0% YoY
Free Cash Flow
24M
+65.0% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-59.7%
Debt / Equity
0.13x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.